Metabolic effects of activation of CCK receptor signaling pathways by twice-daily administration of the enzyme-resistant CCK-8 analog, (pGlu-Gln)-CCK-8, in normal mice

Journal of Endocrinology

Volumn 216, Issue 1, 2013, Pages 53-59

  Irwin, Nigel ^a   Frizelle, Pamela ^a   O'Harte, Finbarr P M ^a   Flatt, Peter R ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

Cholecystokinin (CCK); Food intake; Glucose homeostasis; Insulin sensitivity

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE DERIVATIVE; CHOLECYSTOKININ RECEPTOR; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; CHOLESTEROL; GLU GLN CHOLECYSTOKININ OCTAPEPTIDE; GLUCOSE; INSULIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; (PGLU GLN) CCK 8; (PGLU-GLN)-CCK-8; ANTIDIABETIC AGENT; ANTIOBESITY AGENT; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ OCTAPEPTIDE; DRUG DERIVATIVE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ARTICLE; CALORIC INTAKE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; ENZYME ACTIVATION; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN SENSITIVITY; INTRACELLULAR SIGNALING; LIPID LIVER LEVEL; MALE; METABOLISM; MOUSE; NONHUMAN; PRIORITY JOURNAL; REFEEDING; WEIGHT REDUCTION; ANIMAL; BLOOD; DRUG EFFECT; DRUG POTENTIATION; HYPERGLYCEMIA; INSULIN RESISTANCE; LIVER; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; SECRETION (PROCESS); SIGNAL TRANSDUCTION; TIME; WEIGHT GAIN;

ANIMALS; ANTI-OBESITY AGENTS; BLOOD GLUCOSE; ENERGY INTAKE; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIVER; MALE; MICE; POSTPRANDIAL PERIOD; RECEPTOR, CHOLECYSTOKININ A; SIGNAL TRANSDUCTION; SINCALIDE; TIME FACTORS; TRIGLYCERIDES; WEIGHT GAIN;

MLCS; MLOWN;

EID: 84874443863     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0353     Document Type: Article

References (33)

1. Ahrén B, Pettersson M, Uvnäs-Moberg K, Gutniak M & Efendic S 1991 Effects of cholecystokinin (CCK)-8, CCK-33, and gastric inhibitory polypeptide (GIP) on basal and meal-stimulated pancreatic hormone secretion in man. Diabetes Research and Clinical Practice 13 153-161
2. Ali S, Lamont BJ, Charron MJ & Drucker DJ 2011 Dual elimination of the glucagon and GLP-1 receptors in mice reveals plasticity in the incretin axis. Journal of Clinical Investigation 121 1917-1929
3. Bi S, Chen J, Behles RR, Hyun J, Kopin AS & Moran TH 2007 Differential body weight and feeding responses to high-fat diets in rats and mice lacking cholecystokinin 1 receptors. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology 293 R55-R63
4. Chen S, Turner S, Tsang E, Stark J, Turner H, Mahsut A, Keifer K, Goldfinger M & Hellerstein MK 2007 Measurement of pancreatic islet cell proliferation by heavy water labeling. American Journal of Physiology. Endocrinology and Metabolism 293 E1459-E1464
5. Degen L, Matzinger D, Drewe J & Beglinger C 2001 The effect of cholecystokinin in controlling appetite and food intake in humans. Peptides 22 1265-1269
6. Devlin MJ, Walsh BT, Guss JL, Kissileff HR, Liddle RA & Petkova E 1997 Postprandial cholecystokinin release and gastric emptying in patients with bulimia nervosa. American Journal of Clinical Nutrition 65 114-120.
7. Flatt PR & Bailey CJ 1981 Abnormal plasma glucose and insulin responses in heterozygous lean (ob/C) mice. Diabetologia 20 573-577
8. Gibbs J, Young RC & Smith GP 1973 Cholecystokinin elicits satiety in rats with open gastric fistulas. Nature 245 323-325
9. Habib AM, Richards P, Cairns LS, Rogers GJ, Bannon CA, Parker HE, Morley TC, Yeo GS, Reimann F & Gribble FM 2012 Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology 153 3054-3065
10. Hisadome K, Reimann F, Gribble FM & Trapp S 2011 CCK stimulation of GLP-1 neurons involves {a}1-adrenoceptor-mediated increase in glutamatergic synaptic inputs. Diabetes 60 2701-2709
11. Holst JJ, Vilsbøll T & Deacon CF 2009 The incretin system and its role in type 2 diabetes mellitus. Molecular and Cellular Endocrinology 297 127-136
12. Irwin N, Frizelle P, Montgomery IA, Moffett RC, O'Harte FPM & Flatt PR 2012 Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in animal models of obesity-diabetes. Diabetologia 55 2247-2258
13. Kerr BD, Irwin N, O'Harte FP, Bailey CJ, Flatt PR & Gault VA 2009 Fatty acid derivatised analogs of glucose-dependent tropic polypeptide with improved antihyperglycaemic and tropic properties. Biochemical Pharmacology 78 1008-1016
14. Kuntz E, Pinget M & Damgé P 2004 Cholecystokinin octapeptide: a potential growth factor for pancreatic b cells in diabetic rats. Journal of the Pancreas 5 464-475.
15. Lavine JA, Raess PW, Stapleton DS, Rabaglia ME, Suhonen JI, Schueler KL, Koltes JE, Dawson JA, Yandell BS, Samuelson LC et al. 2010 Cholecystokinin is up-regulated in obese mouse islets and expands β-cell mass by increasing β-cell survival. Endocrinology 151 3577-3588
16. Liddle RA 1994 Cholecystokinin. In Gut Peptides. Biochemistry and Physiology, pp 175-216. Eds JH Walsh & GJ Dockray. New York: Raven.
17. Lo CM, Obici S, Dong HH, Haas M, Lou D, Kim DH, Liu M, D'Alessio D, Woods SC & Tso P 2011 Impaired insulin secretion and enhanced insulin sensitivity in cholecystokinin-deficient mice. Diabetes 60 2000-2007
18. Lubbers T, de Haan JJ, Luyer MD, Verbaeys I, Hadfoune M, Dejong CH, Buurman WA & Greve JW 2010 Cholecystokinin/cholecystokinin-1 receptor-mediated peripheral activation of the afferent vagus by enteral nutrients attenuates inflammation in rats. Annals of Surgery 252 376-382
19. Montgomery IA, Irwin N & Flatt PR 2010 Active immunization against (Pro3)GIP improves metabolic status in high-fat-fed mice. Diabetes, Obesity & Metabolism 12 744-751
20. Moran TH 2008 Unraveling the obesity of OLETF rats. Physiology & Behavior 94 71-78
21. Moran TH, Ameglio PJ, Peyton HJ, Schwartz GJ & McHugh PR 1993 Blockade of type A, but not type B, CCK receptors postpones satiety in rhesus monkeys. American Journal of Physiology 265 R620-R624.
22. Mutt V 1980. Cholecystokinin: isolation, structure and function. In Gastrointestinal Hormones, pp 169-221. Ed GBJ Glass. New York: Raven.
23. Mutt V & Jorpes JE 1968 Structure of porcine cholecystokinin pancreozymin I. Cleavage with thrombin and with trypsin. European Journal of Biochemistry 6 156-162
24. O'Harte FP, Mooney MH, Kelly CM & Flatt PR 1998 Glycated cholecystokinin-8 has an enhanced satiating activity and is protected against enzymatic degradation. Diabetes 47 1619-1624
25. Rehfeld JF 2011 Incretin physiology beyond glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: cholecystokinin and gastrin peptides. Acta Physiologica 201 405-411
26. Rehfeld JF, Friis-Hansen L, Goetze JP & Hansen TV 2007 The biology of cholecystokinin and gastrin peptides. Current Topics in Medicinal Chemistry 7 1154-1165
27. Sato N, Miyasaka K, Suzuki S, Kanai S, Ohta M, Kawanami T, Yoshida Y, Takiguchi S, Noda T, Takata Y et al. 2003 Lack of cholecystokinin-A receptor enhanced gallstone formation: a study in CCK-A receptor gene knockout mice. Digestive Diseases and Sciences 48 1944-1947
28. Schroeder M & Weller A 2010 Anxiety-like behavior and locomotion in CCK1 knockout rats as a function of strain, sex and early maternal environment. Behavioural Brain Research 211 198-207
29. Strader AD & Woods SC 2005 Gastrointestinal hormones and food intake. Gastroenterology 128 175-191
30. Verbaeys I, León-Tamariz F, Buyse J, De Cuyper M, Pottel H, Van BovenM& Cokelaere M 2007 PEGylated cholecystokinin prolongs satiation in rats: dose dependency and receptor involvement. British Journal of Pharmacology 152 396-403
31. Verbaeys I, León-Tamariz F, Pottel H, Decuypere E, Swennen Q & Cokelaere M 2008 PEGylated cholecystokinin is more potent in inducing anorexia than conditioned taste aversion in rats. British Journal of Pharmacology 155 417-423
32. Verbaeys I, León-Tamariz F, Buyse J, Decuypere E, Pottel H & Cokelaere M 2009a Lack of tolerance development with long-term administration of PEGylated cholecystokinin. Peptides 30 699-704
33. Verbaeys I, León-Tamariz F, De Buyser K, Buyse J, Decuypere E, Pottel H & CokelaereM 2009b Dose-response effects of PEGylated cholecystokinin on the behavioral satiety sequence. Physiology & Behavior 98 198-204